Cambium Bio (ASX:CMB), a clinical-stage regenerative medicine company specialising in ophthalmology and tissue repair, has secured a $2.4 million strategic investment from its major shareholder, Zheng Yang Biomedical Technology.
OD6 Metals (ASX:OD6) has commenced advanced metallurgical testwork at the Australian Nuclear Science and Technology Organisation as part of the ongoing optimisation and scale-up of the preferred processing flowsheet for its Splinter Rock Rare Earth Project.